Stem Cells International

Improving the Therapeutic Ability of Mesenchymal Stem/Stromal Cells for the Treatment of Conditions Influenced by Immune Cells


Publishing date
01 Jun 2019
Status
Published
Submission deadline
25 Jan 2019

1Lutheran University of Brazil, Canoas, Brazil

2IBYME–CONICET, Buenos Aires, Argentina

3Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil

4Carlos Chagas Institute–Fiocruz Paraná, Curitiba, Brazil

5CIT NOBA–CONICET-UNNOBA, Junín, Argentina


Improving the Therapeutic Ability of Mesenchymal Stem/Stromal Cells for the Treatment of Conditions Influenced by Immune Cells

Description

Currently, mesenchymal stem/stromal cells (MSCs) are among the most used cells in clinical trials. Whereas many characteristics of these cells have been described to date, aspects of their basic biology that may have an impact on their use in regenerative medicine are still under investigation. The ability of MSCs to interact with immune cells has been documented, and the consequences of this interaction may be beneficial, as seen in cases in which inflammation is reduced. On the other hand, the influence of MSCs on immune system cells may be detrimental in some cases, as demonstrated in experiments in which the effects of MSCs on immune cells favor the development of cancer.

The aim of this special issue is to provide a venue for high quality research articles and reviews that broaden the knowledge on ways to enhance the therapeutic properties of MSCs to treat conditions in which immune system cells may influence outcomes. Manuscripts that provide mechanistic insight on processes that can be used to improve the ability of MSCs to overcome hurdles posed by immune cells are particularly welcome. These may include in vitro and/or in vivo studies, including clinical trials. Additionally, manuscripts describing novel mechanisms by which MSCs modulate the action of immune cells will be considered.

Potential topics include but are not limited to the following:

  • Pretreatment of MSCs with soluble molecules prior to administration in vivo
  • Genetic modifications aimed at improving production of immunomodulatory molecules by MSCs, including studies in which these modified MSCs are administered in vivo to treat a given condition
  • Novel technologies to enhance production and action of acellular mesenchymal stem/stromal cell-derived products (e.g., extracellular vesicles) to treat conditions sensitive to the action of immune cells
  • Novel molecular mechanisms through which MSCs modulate the action of immune cells

Articles

  • Special Issue
  • - Volume 2019
  • - Article ID 6820395
  • - Editorial

Improving the Therapeutic Ability of Mesenchymal Stem/Stromal Cells for the Treatment of Conditions Influenced by Immune Cells

Lindolfo da Silva Meirelles | Marcela F. Bolontrade | ... | Laura Alaniz
  • Special Issue
  • - Volume 2019
  • - Article ID 2509606
  • - Review Article

The Effects of Hypoxia on the Immune-Modulatory Properties of Bone Marrow-Derived Mesenchymal Stromal Cells

Zsolt Fábián
  • Special Issue
  • - Volume 2019
  • - Article ID 7132708
  • - Research Article

MSC-Derived Exosome Promotes M2 Polarization and Enhances Cutaneous Wound Healing

Xiaoning He | Zhiwei Dong | ... | Bei Li
  • Special Issue
  • - Volume 2019
  • - Article ID 7219297
  • - Review Article

Enhancing Mesenchymal Stromal Cell Immunomodulation for Treating Conditions Influenced by the Immune System

Bella S. Guerrouahen | Heba Sidahmed | ... | Chiara Cugno
  • Special Issue
  • - Volume 2019
  • - Article ID 3548917
  • - Review Article

The Immunomodulatory Potential of Wharton’s Jelly Mesenchymal Stem/Stromal Cells

Fernanda Vieira Paladino | Juliana de Moraes Rodrigues | ... | Anna Carla Goldberg
  • Special Issue
  • - Volume 2019
  • - Article ID 9158016
  • - Research Article

IL-10 Gene-Modified Human Amniotic Mesenchymal Stem Cells Augment Regenerative Wound Healing by Multiple Synergistic Effects

Shune Xiao | Guangtao Huang | ... | Dali Wang
Stem Cells International
 Journal metrics
Acceptance rate44%
Submission to final decision76 days
Acceptance to publication35 days
CiteScore7.200
Impact Factor3.869
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.